therawis diagnostics' licensing and development partner QIAGEN launches predictive therascreen PITX2 test in Europe to guide treatment in high-risk breast cancer.
therawis diagnostics and QIAGEN enter into a development and commercialization agreement on predictive biomarkers in oncology.